ASSESSMENT

Targeted Multidrug-Resistant Organism (MDRO) Prevention Strategies

(Recommend implementation regardless of whether residents with *C. auris* or carbapenemase-producing organisms are present)

INFECTION PREVENTION & CONTROL (IPC) INFRASTRUCTURE

IIVI L	NEETION FREVENTION & CONTROL (IFC) INFRASTRUCTORE								
	Questions	Facility I	Practice	Notes (optional)					
1	Is there a dedicated Infection Preventionist on staff?	□Yes	□No						
2	Does this IP have training?	□Yes	□No	What training? ☐ CDC ☐ CMS ☐ APIC ☐ SHEA ☐ Other:					
3	Develop Infection Control policies to address <i>C. auris</i> , carbapenemase-producing organisms and other targeted MDROs	□Yes	□No						
4	Does clinical staff have regular scheduled training in infection prevention?	□Yes	□No	How often? □12 mo □6 mo □3 mo □Q1 mo □Other:					
HANI	D HYGIENE (HH)								
5	Hand hygiene before, during and after the care of resident care	□Yes	□No						
6	Assure HH dispensers/sinks are available	□Yes	□No						
7	Placement of ABHR dispensers outside resident rooms	☐ Ever☐ If not ever # per hallv	ery room,						
8	Placement of ABHR dispensers inside resident rooms	□Yes	□No						
9	Have a system in place to educate and audit HH amongst staff (optimally to address different areas, providers and shifts)	□Yes	□No						
PERS	ONAL PROTECTIVE EQUIPMENT (PPE) & PRECAUT	ION & PATI	ENT PLACE	MENT					
10	Review transmission-based precautions (TBP) signage	□Yes	□No						
11	Review policies and procedures for the placement of residents on TBP	□Yes	□No						
12	Assure PPE is available in proximity to TBP rooms	□Yes	□No						
13	 Educate and audit staff related to: understanding of standard and transmission-based precautions when to use PPE/isolation equipment Donning and doffing of PPE correctly 	□Yes	□No						
14	Educate patients and family regarding PPE	□Yes	□No						

ENVIRONMENTAL SERVICES (EVS)						
15	Review cleaning/disinfectant agents	□Yes	□No			
16	Where do you use cleaning products effective against <i>C. auris</i> (i.e., EPA List P product) or other targeted MDROs (e.g., carbapenemase-producing organisms).	☐ In isolat ☐AII PCA ☐Other:	ion rooms			
17	Cleaning and disinfection of equipment and environment	□Yes	□No			
18	EVS staff knowledgable of contact times for type of disinfectant used	□Yes	□No			
19	EVS staff knowledgable of appropriate concentration for type of disinfectant used (if solution is not pre-mixed)	□Yes	□No			
20	Assure EVS staff wear PPE correctly	□Yes	□No			
21	A system for who cleans which items, or what interval and what agent (e.g. responsibilities clearly delineated between EVS and front line staff)	□Yes	□No			
22	Ensure thorough, appropriate cleaning/disinfection of all reusable medical equipment or supplies	□Yes	□No			
23	Infection prevention and control department involved in EVS policies	□Yes	□No			
24	Have a system in place to educate and audit EVS	□Yes	□No			
25	Evaluate environmental hygiene (i.e., florescent marker, ATP bioluminescence, swab culture)	□Yes	□No			
26	Educate healthcare personnel (i.e. RNs, LVNs, CNAs) on cleaning, disinfection, and contact time for disinfectant used and other EVS duties.	□Yes	□No	How often? □12 mo □6 mo □3 mo □1 mo □Other:		
INTE	R-FACILITY COMMUNICATION					
27	Flag case patients' medical records	□Yes	□No			
28	Receive clear precautions information and MDRO infection/colonization history on admission	□Yes	□No			
29	Convey clear precautions information and MDRO infection/colonization history on transfer or discharge	□Yes	□No			
30	Use of an inter-facility transfer form/sheet	□Yes	□No			
OTHE	R					
31	Timely notification from the laboratory of pertinent clinical and infection prevention staff whenever a highly resistant MDRO is identified	□Yes	□No			

32	Regularly review invasive devices (CVC, urinary catheter, etc) for indication and discontinue promptly when no longer needed	□Yes	□No	
33	Implement an antimicrobial stewardship program with antifungals included	□Yes	□No	
34	Residents determined to be at high risk of colonization with <i>C. auris</i> or carbapenemase-producing organisms (CPOs) are tested for colonization upon admission	□Yes	□No	
35	Other horizontal prevention measures not listed; if yes, please describe	□Yes	□No	
	ris Control Strategies mmend implementation when residents with <i>C. au</i>	<i>ıris</i> or other	targeted N	ADROs are present)
36	Residents with <i>C. auris</i> are assessed for risk of transmission to other residents	□Yes	□No	
37	Contact Precautions or Enhanced Barrier Precautions are implemented for residents with C. auris or other targeted MDROs	□Yes	□No	
38	Dedicated equipment for residents with a history of <i>C. auris</i> or other targeted MDROs	□Yes	□No	
39	Review the cohorting of residents and staff	□Yes	□No	
40	When a resident is newly identified with <i>C. auris</i> , contacts are screened for <i>C. auris</i> colonization	□Yes	□No	
41	When multiple residents with <i>C. auris</i> are present at the facility, the primary caregiving staff dedicated to those residents	□Yes	□No	
42	Facility using agent effective against <i>C. auris</i> to disinfect resident rooms and shared equipment	□Yes	□No	
STAF	FOBSERVATIONS			
43	Hand Hygiene Adherence		_%	
44	Contact Precaution and/or EBP Adherence		_%	
45	Environmental Services (EVS) Adherence		_%	
43	Fluorescent Marker check (if used)		_%	
	at guidance and/or resources do you need from Pu uris, carbapenemase-producing organisms, or othe			•

RECOMMENDATIONS	
Hand Hygiene	
	_
Environmental Cleaning	
Contact Precautions and/or Enhanced Barrier Precautions	
ADDITIONAL COMMENTS:	